Compare AstraZeneca plc (AZN) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Capri Holdings Ltd — how do they compare? AstraZeneca plc trades at $168.32 (market cap $253.13B), while Capri Holdings Ltd trades at $16.73 (market cap $1.91B). The key difference: AstraZeneca plc is far larger — about 132.5× Capri Holdings Ltd's market cap, and AstraZeneca plc pays a 1.92% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| AZN | CPRI | |
|---|---|---|
Market Cap | $253.13B | $1.91B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $27.66 |
52-Week Low | $137.44 | $16.68 |
Enterprise Value | $279.37B | $3.20B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
CPRI trades at $17.46, down 3.22% on the day, with a bearish technical signal from moving averages and oscillators neutral. The company reported a net loss of $1.18 billion in 2025 despite a gross profit margin of 62.26%. Recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo, with management projecting fiscal 2027 growth. Analyst consensus is a buy rating with a $23.33 price target, implying significant upside from current levels.
The investment case hinges on successful execution of the two-brand strategy and return to profitability. Key risks include sustained luxury demand weakness and high debt levels, while potential rewards include valuation upside if earnings guidance is met. The stock presents a high-risk, high-reward opportunity contingent on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
